Since its discovery in the 1990s, programmed cell death protein 1 (PD-1) has been regarded as a leading target in cancer ...

Cancer immunotherapy drugs called immune checkpoint inhibitors take the brakes off the body’s immune system, allowing it to ...

Since its discovery in the 1990s, "programmed cell death protein 1," or PD-1, has been regarded as a leading target in cancer treatments.

Scientists have discovered significant discrepancies in PD-1 between humans and rodents, indicating that common lab models ...

Cadonilimab is under clinical development by Akeso and currently in Phase II for Metastatic Renal Cell Carcinoma.

A novel molecular tool developed by a Lehigh University professor of biological sciences is enabling scientists to precisely ...

Artificial intelligence-enabled discovery of a RIPK3 inhibitor with neuroprotective effects in an acute glaucoma mouse model ...

Cadonilimab is under clinical development by Akeso and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II drugs for Endometrial Cancer have a 22% phase transition success ...

Westlake University in China and the California Institute of Technology have designed a protein-based system ... to stay alive or undergo programmed cell death. Cells naturally process multiple ...